




Management Update FY2023



DISCLAIMER

The information in this presentation has not been independently verified. iX Biopharma Ltd (the “**Company**”) makes no representation or warranty (whether express or implied) whatsoever in this presentation, & no reliance should be placed on the information or opinions contained in this presentation. The Company assumes no responsibility or liability whatsoever (in negligence or otherwise) for any information or opinions contained herein nor for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

This presentation is strictly private & confidential, & is meant solely for your information only. Nothing in this presentation is or shall be considered to be an offer for the solicitation, sale or subscription of any securities. This presentation may also contain forward-looking statements that involve known or unknown risks, uncertainties & other factors that may cause the actual results, performance or achievements (collectively, the “**Results**”) of the company & its subsidiaries (the “**Group**”) to be materially different from any future Results. The Company makes no assurance that any future events, projections or assumptions will respectively occur, be achieved or are correct. The Company does not assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.





AGENDA

- 1) Pharmaceuticals Update
- 2) About MeltMed
- 3) Market Outlook



Pharmaceuticals Update

Pharmaceutical Pipeline



S/N	Product	Indication	Pre Clinical	P1	P2	P3	Approval	Remarks
1	Wafesil	Male Erectile Dysfunction						Out-licensed to CRPCG
2	Wafermine	Complex Regional Pain Syndrome						US FDA Orphan Designation
3	iXB-120	Acute agitation in Dementia						
4	iXB-321	Vaccine Delivery						
5	iXB-322	Respiratory Viral Prophylaxis						
6	iXB-320	Anorexia in HIV/CINV						



Wafermine

Wafermine (SLS-003), CRPS Development Program



- 1) Wafermine, sublingual ketamine wafer, is being developed to treat Complex Regional Pain Syndrome
- 2) Seelos Therapeutics is preparing for commencement of Phase 2 CRPS study
 - a) Contract Research Organization engaged
 - b) Clinical Trial Sites identified
 - c) Protocol design near complete

“A Phase 2, 3-stage, Open Label Study of the Safety, Tolerability, and Therapeutic Effects of SLS-003 (Wafermine), sublingual racemic ketamine in Participants with Complex Regional Pain Syndrome”

Study Objectives

- ✓ Establish safety and tolerability
- ✓ Identify efficacious dosing regimen

- 3) We received orphan drug designation for CRPS by the US FDA; advantages
 - a) market exclusivity, 7 years
 - b) financial incentives, including waiver of NDA filing fee ~US\$4M
 - c) higher product pricing



iXB-120

iXB-120, Addressing Agitation in Alzheimer's



- 1) iXB-120 is a novel, sublingual dexmedetomidine wafer;
 - a) Dexmedetomidine is an alpha-2 receptor agonist
 - i. Approved for sedation by IV administration
 - ii. Recently approved for agitation in psychiatric patients by sublingual film

- 2) iXB-120 is being developed to treat agitation in Alzheimer's disease patients
 - a) Agitation means verbally and physically aggressive behavior
 - b) Current options for "as required" use are not effective and include;
 - i. Anti-psychotics and benzodiazepines with severe adverse effects including over-sedation
 - ✓ Dexmedetomidine has a novel mechanism of action with a better side effect profile
 - ii. Physical restraints, e.g. strapped to chair/bed

- 3) iXB-120 will address a large unmet need for dementia patients suffering from agitation

- 4) Next Step
 - ✓ File IND with US FDA to commence Phase 2 clinical study

DEX-001: Phase 1 PK Study Results




➤ Study Design:

- 1) 4-way crossover study, evaluating SL 30mcg v SL 50mcg v SL 100mcg v IV 20mcg
- 2) 14 healthy volunteers confined for 8 days, PK blood sampling out to 24 hours post each dose

➤ Results:

- 1) High absolute bioavailability ~70-80%
- 2) Fast absorption: detectable drug levels in plasma as early as 5 minutes post dose; time to peak drug concentration ~1.5h
⇒ fast onset of action
- 3) Drug exposure was dose proportional across dosing range







iXB-321

iXB-321, Sublingual Wafer Vaccine

- 1) Respiratory viruses infect the body via the mucosa (nose, mouth & throat)
 - ✓ The mucosa is the first-line of defence, therefore a strong protective mucosal immunity is important
- 2) Vaccines are administered by injection into the muscle or under the skin & generally produce poor mucosal immunity
- 3) The world is looking for a better way to deliver vaccines via the mucosa to stop viral spread ...



- 4) Sublingual vaccination can produce both strong mucosal and systemic immunity, potential to address the issue of viral spread, including in vaccinated individuals

iXB-321, Wafer Vaccine Development



1) Formulation Study

a) H1N1 influenza vaccine (haemagglutinin, HA 15mcg) incorporated into wafer

b) Results

- ✓ Demonstrated full antigen (HA) activity (~100%) on in-vitro SRID potency laboratory testing

Single Radial Immuno-Diffusion (SRID) Assay





Fig.1: Standard RID Assay



2) Next Step

- ✓ Pre-clinical animal study to determine wafer vaccine immunogenicity in ferrets

Advantages of Sublingual Wafer Vaccines

Injection

Sublingual

	Injection		Sublingual
Transport & storage	Cold chain shipping ✗ Refrigerated/ frozen storage ✗	VS	Simple logistics ✓
Administration	Requires trained personnel for administration ✗ Cost for syringes and disposal ✗ Risk of needle-stick injuries ✗		Self-administration ✓ No additional administration costs ✓
Compliance	Poor compliance ✗		High compliance ✓

- The competitive environment for oral COVID-19 vaccines is limited. As with influenza, there are no mRNA vaccines with oral administration in the pipeline.
- Furthermore, direct competitors for iX Biopharma's vaccine could not be identified.
- Hence, competition for the sublingual mRNA-based COVID-19 vaccine is likely to be low.

BIO SCIENCE VALUATION
Capturing Value from Innovation



iXB-322

iXB-322, Low-Dose Interferon Sublingual Wafer

- 1) Interferons (IFNs) are approved for various conditions including hepatitis B & C, melanoma, lymphoma and multiple sclerosis
 - a) Administered by injection (IV, IM, SC) at very high doses (3-50 million IU)
 - ✓ Side effects are common due to immune system over-stimulation
- 2) They are human proteins that serve as the primary responders against viral infections and tumours
- 3) Many viruses (including SARS-CoV-2 and Influenza) inhibit IFN production by the oral mucosa to thwart the host defense
- 4) Clinical studies have shown that delivering low dose IFN (≤ 10000 IU) directly to the oral mucosal surface may prevent and also treat respiratory illnesses, including SARS-CoV-2, Influenza and RSV




Figure 1: Antiviral actions of Interferon


Ref: <https://www.lecturio.com/concepts/interferons/>

iXB-322 Interferon Wafer Development

1) Formulation Study Completed

- ✓ Promising results;
- a) 100% activity demonstrated with established in-vitro testing using cytopathic effect assay in lung adenocarcinoma cell line (A549) with encephalomyocarditis virus (EMCV)
- b) 6 months stability results indicate wafers are shelf stable at both 4°C and 20°C

Figure 1: A549/EMCV CPE Assay for Alpha IFN



Interferon alpha 2b
165AAs, ~20kDa

2) Next step

- ✓ Engage with FDA on clinical development pathway for respiratory viral prophylaxis and treatment (Influenza, Covid, RSV)



About MeltMed

MeltMed Update

- MeltMed offers a range of innovative supplements designed to fight aging at the source, enhance the quality of lives and increase healthspan
- MeltMed products combine potent ingredients with WaferiX delivery technology to ensure better absorption and effectiveness
- Soft launched in end-Sep 2023 with 2 initial products, Regenerate NAD+ wafers & Radiance GSH wafers



REGENERATE
Pure NAD+ Supplement



RADIANCE
Glutathione Skin Beauty Supplement





Rejuvenate your life with **REGENERATE**

DIETARY SUPPLEMENT

REGENERATE

NAD+ 50mg per wafer

30 Dissolvable Wafers

meltmed

Prevents free radicals*

Supports vitality & healthy aging*

Supports cellular health*

Aids energy production*

GMP

VEGETARIAN

GLUTEN FREE

* These statements have not been evaluated by the Food and Drug Administration, FDA. This product is not approved by the FDA and is not intended to treat, cure or prevent any disease.

Source: 1. Time: Is an anti-aging pill on the horizon? <https://time.com/5159879/is-an-anti-aging-pill-on-the-horizon/>



Brighten & Beautify with RADIANCE

The image shows a box of RADIANCE dietary supplement. The box is primarily red with a blue section on the right side. Text on the box includes "DIETARY SUPPLEMENT", "RADIANCE", "Glutathione 50mg per wafer", and "30 Dissolvable Wafers". The Meltmed logo is visible on the blue section. Five callout boxes with arrows point to different parts of the box, each containing a skin benefit claim. At the bottom right of the box, there are three circular icons: GMP, Vegetarian, and Gluten Free.

Mother of all antioxidants

Reduce fine lines & wrinkles by up to 50%*

Increase in skin elasticity by up to 226%*

Increase in skin smoothness by up to 70%*

Increase in skin gloss & luminosity by up to 60%*

DIETARY SUPPLEMENT

RADIANCE

Glutathione 50mg per wafer

30 Dissolvable Wafers

meltmed

GMP

VEGETARIAN

GLUTEN FREE

Improvement of skin elasticity and smoothness in 100% of participants. Results within 8 weeks based on a clinical trial of 34 female participants with signs of skin aging, evaluated objectively with skin measurement instruments.

* These statements have not been evaluated by the Food and Drug Administration, FDA. This product is not approved by the FDA and is not intended to treat, cure or prevent any disease.



No need for painful,
time consuming
IV drips



Wafer it
anytime,
anywhere







NAD+

Glutathione

CBD

CBD + Melatonin



← Launching in 2024 →

REGENERATE
Pure NAD+ Supplement – 50mg per wafer

RADIANCE
Glutathione Skin Beauty Supplement – 50mg per wafer



Market Outlook

Market Outlook



1) Since the pandemic,

- Russia-Ukraine conflict led to volatile energy prices, global supply chain disruption, and persistent inflation;
- Higher interest rates led to tighter monetary conditions; and
- US-China geopolitical tension continued to grow and threaten economic stability

Investor sentiment is poor and negatively affected capital markets

2) Company will closely monitor the economic situation and determine its next steps when there is better visibility of financial market conditions



Thank You